Elicio Therapeutics, Inc. announced preliminary clinical observations supporting the evaluation of ELI-002 7P with checkpoint inhibition and plans to conduct a Phase 1 study in first-line metastatic mutant KRAS pancreatic ductal adenocarcinoma, pending funding. Elicio Therapeutics, Inc. is a biotechnology company focused on developing immunotherapy treatments.
